We are live on ! Find out more
EBAC

European Biotech Acquisition Corp. Class A Ordinary Shares
EBAC

Delisted

EBAC was delisted on the 2nd of March, 2023.

Back to rankings

50 hedge funds and large institutions have $86.6M invested in European Biotech Acquisition Corp. Class A Ordinary Shares in 2022 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

250% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 2

67% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 3

18% more capital invested

Capital invested by funds: $73.3M → $86.6M (+$13.3M)

9% more funds holding

Funds holding: 46 → 50 (+4)

Holders
50
Holders Change
+4
Holders Change %
+8.7%
% of All Funds
0.86%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
5
Reduced
3
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BNP Paribas Financial Markets
BNP Paribas Financial Markets
France
+$4.89M
2
PC
Periscope Capital
Ontario, Canada
+$3.32M
3
GCL
Glazer Capital LLC
New York
+$2.83M
4
FTCM
First Trust Capital Management
Illinois
+$2.26M
5
MF
Magnetar Financial
Illinois
+$1.3M

Top Sellers

Rank Fund Capital Flow
1
SCM
Suvretta Capital Management
New York
-$2.94M
2
GCM
Ghisallo Capital Management
Massachusetts
-$1.97K
3
CSS
Cubist Systematic Strategies
Connecticut
-$197
4
RCM
Radcliffe Capital Management
Pennsylvania
-$10
Name Holding Trade Value Shares
Change 		Change in
Stake
GCL
1
Glazer Capital LLC
New York
$9.86M +$2.83M +287,251 +41%
PC
2
Periscope Capital
Ontario, Canada
$8.36M +$3.32M +336,744 +66%
Millennium Management
3
Millennium Management
New York
$5.91M – – –
Macquarie Group
4
Macquarie Group
Australia
$5M – – –
LA
5
Linden Advisors
New York
$4.94M – – –
Marshall Wace
6
Marshall Wace
United Kingdom
$4.5M +$167K +16,901 +4%
BNP Paribas Financial Markets
7
BNP Paribas Financial Markets
France
$3.69M +$4.89M +496,000 New
SC
8
Sculptor Capital
New York
$3.5M – – –
PMAM
9
Picton Mahoney Asset Management
Ontario, Canada
$2.73M – – –
WP
10
Woodline Partners
California
$2.72M – – –
Bank of America
11
Bank of America
North Carolina
$2.57M – – –
D.E. Shaw & Co
12
D.E. Shaw & Co
New York
$2.56M +$3.95K +400 +0.2%
MI
13
MMCAP International
Cayman Islands
$2.48M – – –
MF
14
Magnetar Financial
Illinois
$2.29M +$1.3M +132,163 +134%
FTCM
15
First Trust Capital Management
Illinois
$2.27M +$2.26M +228,599 New
RCM
16
Radcliffe Capital Management
Pennsylvania
$2.12M -$10 -1 -0%
AA
17
AQR Arbitrage
Connecticut
$1.99M – – –
KL
18
KIM LLC
Kansas
$1.98M – – –
Alyeska Investment Group
19
Alyeska Investment Group
Illinois
$1.49M – – –
MCM
20
Moore Capital Management
New York
$1.24M – – –
GCM
21
Ghisallo Capital Management
Massachusetts
$1.24M -$1.97K -200 -0.2%
FTCM
22
Fir Tree Capital Management
New York
$1.05M – – –
State of Wisconsin Investment Board
23
State of Wisconsin Investment Board
Wisconsin
$1M – – –
DCM
24
Dupont Capital Management
Delaware
$992K – – –
Hudson Bay Capital Management
25
Hudson Bay Capital Management
Connecticut
$992K – – –
1
2 3

EBAC Hedge Fund Activity: Q3 2022 in Review

50 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in European Biotech Acquisition Corp. Class A Ordinary Shares (EBAC) for Q3 2022, worth a combined $86.6M — up 18% from $73.3M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new EBAC positions and 2 closed out — a net gain of 5 holders — while 5 added to existing stakes and 3 trimmed.

The largest buyer was BNP Paribas Financial Markets, opening a new position worth an estimated $4.89M. The largest seller was Suvretta Capital Management, exiting entirely with an estimated $2.94M sold.

  • 50 institutional investors held European Biotech Acquisition Corp. Class A Ordinary Shares (EBAC) as of Q3 2022, up from 46 in Q2 2022.
  • Funds reported $86.6M of European Biotech Acquisition Corp. Class A Ordinary Shares stock for Q3 2022, up 18% quarter-over-quarter.
  • 7 funds opened new European Biotech Acquisition Corp. Class A Ordinary Shares positions in Q3 2022 and 2 closed out, a net change of +5 holders.
  • The largest European Biotech Acquisition Corp. Class A Ordinary Shares buyer in Q3 2022 was BNP Paribas Financial Markets, an estimated $4.89M added.
  • The largest European Biotech Acquisition Corp. Class A Ordinary Shares seller in Q3 2022 was Suvretta Capital Management, an estimated $2.94M sold.

Based on aggregated 13F filings for Q3 2022.